Akers Biosciences Share Discussion Threads

[mcmather] 17/2/2016 22:59

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 12 April 2005:
And from the same RNS as per #3079; "We now also have the necessary financial resources to expand our organization, as well as to establish a presence in UK and European markets". Can't understand why some mischievous blighter christened him Dr Mitty??

[mcmather] 17/2/2016 22:56

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 12 April 2005:
The Company has started to build an internal sales and marketing organization to manage the launch of its own brands of products into the marketplace, initially its tests for heparin platelet factor-4, lithium, cholesterol, and alcohol breathalyzers.

The Company is starting a trial in conjunction with Pfizer Inc. to introduce its cholesterol test to US physicians and consumers, through a program involving Pfizer's cholesterol-lowering drug Lipitor.

The Company will introduce its products in the UK and certain EU countries through new alliances with Helena Biosciences Europe and Advanced Rapid Diagnostics Ltd.

Ray Akers said: "The pieces of the puzzle have all come together". Notwithstanding whether he was blatantly lying here or just plain deluded, this still made me chuckle. What an absolute plank.

[mcmather] 17/2/2016 22:46

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 22 February 2005:
Akers Biosciences Inc. announced today that it has signed an agreement establishing an alliance with Alco Industries to distribute certain of Akers' rapid diagnostic tests to US retail markets. Akers has already begun shipments of product to Alco; the size of the re-orders will be determined by the response from these initial orders.

Dr. Ray Akers said, "The broad reach of Alco into the US retail marketplace provides us with a powerful route to distribute many of our products. We are fortunate to form an alliance with a partner with proven abilities in creating a significant impact with its products and services in many different market segments."

[mcmather] 17/2/2016 22:43

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 14 February 2005:
Akers Biosciences, Inc. is pleased to announce today that it has signed an agreement with Oryx Pharmaceuticals Inc. to sell and distribute its rapid test for Heparin Platelet Factor-4 (HPF-4) antibodies in Canada.

Dr. Ray Akers said, "We believe the PIFA� HPF-4 Antibody Assay will address a critical need not only in cardiac surgeries, but also in other types of surgeries, and emergency medicine, and improve the standard of care for patients undergoing anticoagulant therapy. We also believe that Oryx Pharmaceuticals is perfectly positioned to bring this product to these marketplaces in Canada."

[mcmather] 17/2/2016 22:37

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 14 January 2005:
Towards the end of 2004, the Company experienced problems with the supply of
key components for the company's PIFA HPF4 test from third party suppliers.
These issues unfortunately prevented Akers from shipping any significant volume
of this product as was originally intended.

As a result, the Company announces that a substantial portion of revenue from
sales of the Company's PIFA Heparin/PF 4 antibody rapid test, estimated to be approximately $3 million, have been delayed and revenue for 2004 will therefore fall short of expectations.

Separately, the Company is pleased to announce that it has already received
orders for its breathalyzer products for shipment in the first half of 2005
totalling approximately $1million, nearly double the entire amount of product
shipped in 2004.

Dr. Raymond Akers said "While we are disappointed that we were not able to recognize the initial revenue from our PIFA HPF4 test in the second half of 2004, we are heartened to see that our manufacturing problems have been solved and the shipments are under way. Moreover, the initial market response to this product has been positive. We are confident that we will be able to build revenues for this product while simultaneously growing revenues from other products in our portfolio, such as our breathalyzers and lithium tests."

Another open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences but does this we have revenue, errr no we don't, but the future is great repeat itself at any time, say, up until the latest set of results that were published 13 November 2015?

[mcmather] 17/2/2016 22:32

No question this time to Dr Raymond F. Akers Jr., Ph.D. or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences but note the right way to correct a mistruth:

CORRECTION RNS 25 October 2004:
Owing to a system error earlier today the company's Q3 Update announcement was
incorrectly released under the name of Akers Biosciences Inc. The company would like to point out that the announcement is in no way connected to Akers Biosciences Inc and concerns only the business of Sopheon plc.

[mcmather] 17/2/2016 22:28

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 25 October 2004:
Our sales teams are busy with a substantial number of opportunities slated for closure in the fourth quarter, and December in particular.

[mcmather] 17/2/2016 22:24

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 29 September 2004:
The Company has started to build an internal sales and marketing organization to manage the launch of its own brands of products into the marketplace, initially through its tests for heparin platelet factor-4 and Lithium.

Ray Akers said: "We have gained serious momentum with the receipt of product approvals and the establishment of significant distribution and business relation".

That last bit was said over 10 years ago and has been said virtually every year since. Open question to Dr Raymond F. Akers Jr., Ph.D. or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences, will this now proven to be misleading line also form part of the formal results for 2015?

[mcmather] 17/2/2016 22:16

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 23 September 2004:
Akers Biosciences, Inc. is pleased to announce today that it has signed an agreement with Helena Laboratories Corp. to distribute its rapid test for Heparin Platelet Factor-4 (HPF-4) antibodies worldwide.

Dr. Ray Akers said, "We believe the PIFA(R) HPF-4 Antibody Assay will address a critical need not only in cardiac surgeries, but also in other types of surgeries, and emergency medicine, and improve the standard of care for patients undergoing anticoagulant therapy."

This is and has been Aker's main device / seller subsequently. Can Dr Raymond F. Akers Jr., Ph.D. or Vigo Communications, in their capacity as the Public Relations agent to Akers Biosciences, provide an answer in terms of why the sales of this 'critically needed' product, flat-lined for years and now appear to be falling dramatically despite what Dr Raymond F. Akers Jr., Ph.D. has publicly stated over the last decade or so?

[mcmather] 17/2/2016 22:10

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 13 July 2004:
In our statement of 2003 results dated 7 June, 2004, we noted an increase in
the sales rate in the first quarter of 2004 over the rate in the second half of
2003, and that prospects for further sales growth were positive. In fact, the
sales rate further increased in the second quarter of 2004.

In addition, we previously noted that a substantial portion of future sales
would be dependent upon FDA approval for certain products. We subsequently
announced on 14 June, 2004, that we have received FDA approval for our heparin/
platelet factor 4 (HPF4) assay, the first rapid assay for the identification of
patients at risk for developing heparin-induced thrombocytopenia and thrombosis
syndrome (HITTS), a severe allergic-like side effect associated with the use of
the anticoagulant heparin. On 24 June, 2004, we announced a placing of shares
that raised 847,000 sterling, before expenses, to be used in the launch of the
HPF4 test. The market response to the HPF4 test has been very encouraging, and
the company plans to fulfill its first orders for this product in early August.

We would also like to note that the rate of sale of our alcohol breathalyzers
is substantially increased over the rate in 2003.

[mcmather] 17/2/2016 22:07

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 28 June 2004:
Akers Biosciences Inc. is pleased to announce today that it has developed and introduced the Biosniffer(tm), a continuous monitoring detector designed to provide real-time information on the airborne release of biowarfare agents. Each system is designed to provide visual, auditory and electronic warning signals to indicate that a biowarfare agent release event has occurred.

Dr. Ray Akers said, "Much of the world now lives under the threat of bioterrorism, and we at Akers Biosciences are proud to contribute in some small way a means of mitigating that threat. We are very excited about the possible impact that the Biosniffer can have on both military and civilian sectors. In addition, we look forward to working with Kuchera Defense Systems to commercialize these products to both the military and government."

[norbus] 21/1/2016 11:22

Nasdaq must have a monitoring unit; AKR was never suited to float; TN want it as step to acquisition trail, but A presumable blocked it; the UK institutional investor was found for that purpose .

[mcmather] 21/1/2016 10:16

Still reviewing all (usual lack of time) but there do appear to be regular instances in which reported 'deals' transpired to be 'no deals'. Trying to ascertain whether this was simply the run and flow of a bona fide business operation. Or blatant misrepresentation? Maybe Vigo Communications (Public Relations) will be able to assist in due course.

[norbus] 21/1/2016 10:07

! saw that confrontation from Fury; Dr Akers is heading for the Knakers ; Walter Mitty was a nice decent character and nothing like Raymond; Class action anyone? or Nasdaaq regulaters?

[mcmather] 20/1/2016 23:57

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 14 June 2004:
June 14 , 2004 (ie nearly 16 years ago at the time of writing this post...)--Akers Biosciences Inc. is pleased to announce today that it has received market clearance from the U.S. Food and Drug Administration ("FDA") for its rapid test for Heparin / Platelet Factor-4 (HPF4) antibodies..."We believe the HealthTEST� HPF-4 Antibody Assay will address a critical need not only in cardiac surgeries, but also in other types of surgeries, and emergency medicine, and improve the standard of care for patients undergoing anticoagulant therapy."

[mcmather] 20/1/2016 23:39

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 18 February 2004:
February 16, 2004--Akers Biosciences Inc. announces today that it has submitted a 510(k) Premarket Notification to the United States Food and Drug Administration seeking market clearance for its rapid test for Heparin/Platelet Factor-4 (HPF-4) antibodies. "We believe the HealthTEST(R) HPF-4 Antibody Assay will address a critical need in hematology and cardiology, and improve the standard of care for patients undergoing heparin therapy."

[mcmather] 20/1/2016 23:35

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 10 September 2003:
"The first half of 2003 has laid a solid foundation for sales growth in the second half of the year. Our product pipeline is full of products in various stages of development, clinical trials, and regulatory approvals. In addition, new partners and established partners are beginning to penetrate their markets with our products. We are experiencing a greater than anticipated demand for our nutrition-related products from the network marketing organizations we are working with through Vitarich. We also anticipate an exciting entry into the neuropsychiatric markets in the second half of 2003 upon FDA approval of our lithium test. This activity, combined with a good pipeline of new products, should provide a strong platform for future growth."

[mcmather] 20/1/2016 23:32

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 18 June 2003:
"While this past year did not result in revenues that met our expectations, nonetheless significant milestones were achieved........In addition, we have solidified sales and marketing relationships with contracts that should propel our growth in the years to come.

[mcmather] 20/1/2016 23:31

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 18 June 2003:
Significant expansion of corporate infrastructure in sales and marketing, manufacturing, product development, and regulatory affairs.

[mcmather] 20/1/2016 23:29

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 18 June 2003:
Company successfully transitioned from development to operating stage.

[mcmather] 20/1/2016 23:28

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 22 Jan 2003:
With these agreements, the Company is now beginning to deliver a more secure long term business base in the US and other developed markets, reflecting the efficacy and innovation of our rapid testing technology."

[mcmather] 20/1/2016 23:26

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 22 Jan 2003:
The company estimates that there are over 3 million patients worldwide currently receiving Lithium prescriptions. Akers new technology allows for the determination of lithium levels in approximately 2 minutes, and we believe is the first rapid, point of care test for lithium on the market.

[mcmather] 20/1/2016 23:25

Open question to Dr Raymond F. Akers Jr., Ph.D. to answer or Vigo Communications in their capacity as the Public Relations agent to Akers Biosciences. What went wrong and who is to blame here?

RNS 14 Nov 2002:
Despite the delays in a number of revenue generating opportunities, the Company has continued confidence in the strength of its technology and is building strong long term relationships which should reflect in significantly increased sales and profits in 2003 and beyond